Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: nestegg who wrote (5206)	12/30/1997 2:24:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

nestegg, the XOMA Fact Sheet has been updated as of earlier today 29 DEc. Not sure it is in final version, but it's there.

To: nestegg who wrote (5206)	12/30/1997 8:03:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Glasgow scales are ancient but they do have strong clinical relevance. One problem of the Glasgow scales is that there is probably not great validity of the prognostic value of the modified version for use in menigoncoccemia, the original version was designed for head trauma patinets. This is one of the arguments from Dumbar, the clinician that sent the critic letter tothe Lancet. But there were many other laboratory and clinical data use to asses the critical status of the patients, including classic ones like the coagulopathy tests, and new ones like the measurement of TNF, LPS and IL-6 inflamatory shock markers. Now sulfas are rarely use for prevention, Rifampin is more effective and safer than sulfas. Also, it is more effective than masks unless one the 3M ultrafiltration (and asphyxiating) type of masks use for Tuberculosis prevention. Or one could use one of the suits from the Intel microchip plant, they are the best.